linjc16/ctgov huggingface dataset:
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30

Study Overview
=================
Brief Summary
-----------------
Determine if Cetaphil DermaControl Oil Control Moisturizer SPF 30 proves to be a contact sensitizer or irritant in certain individuals

Official Title
-----------------
Cetaphil Dermacontrol Oil Control Moisturizer SPF 30- 100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)

Conditions
-----------------
Skin Irritation

Intervention / Treatment
-----------------
* Other: Cetaphil DermaControl Oil Control Moisturizer SPF 30


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Not currently under a doctor's care Free of dermatological or systemic disorder which would interfere with the results Free of any acute or chronic disease Will complete a preliminary medical history form and are in general good health Can read, understand, and sign informed consent Exclusion Criteria: Under 18 years old Currently under doctor's care Currently taking any medication History of acute or chronic disease Diagnosed with chronic skin allergies Pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cetaphil DermaControl Oil Control Moisturizer SPF 30<br>All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30 | Other: Cetaphil DermaControl Oil Control Moisturizer SPF 30<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| area of erythema and edema to test reaction of skin to product | 9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks will be conducted to test the reaction of the skin to the test product | 3 consecutive weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Determine, Hypoallergenicity, Cetaphil DermaControl Oil Control Moisturizer SPF 30
Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the geriatric patients with the non-geriatrics undergoing outpatient unilateral herniorrhapy in terms of local anesthesia, sedation, recovery and early morbidity.

Detailed Description
-----------------
A retrospective data analysis will be conducted and the patient records will be evaluated for patient characteristics local anesthesia, sedation, recovery and early morbidity.

Official Title
-----------------
Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy at Our Institution

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: local infiltration anesthesia and sedation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with a unilateral inguinal hernia undergoing herniorrhaphy Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Geriatri<br>patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation | Procedure: local infiltration anesthesia and sedation<br>* the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents<br>* Other names: local anesthesia and sedation;|
| non-geriatri<br>patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation | Procedure: local infiltration anesthesia and sedation<br>* the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents<br>* Other names: local anesthesia and sedation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| discharge time |  | postoperative 2 hours | 
| discharge delay |  | postoperative 2 hours | 
| local anesthetic doses |  | intraoperative | 
| sedative doses |  | intraoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications (hypertension, tachycardia, bradycardia, hypotension, nausea, vomiting) |  | intraoperative | 
| early morbidity |  | postoperative 2 hours | 
| morbidity |  | postopative 1 week |
Non-contact Proactive Remote Monitoring of COPD Exacerbations

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: Can an exacerbation be detected before the person recognizes they are unwell? What are the biological signals which provide the best indication of decompensation? How does this indication of decompensation compare to a daily CAT? Participants will be asked to place a device, DistaSense, on top of their mattress and then sleep as normal. In addition, they will be asked to complete a daily CAT.

Official Title
-----------------
Non-contact Proactive Remote Monitoring to Facilitate Early Detection of Exacerbations in Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
COPD Exacerbation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of COPD 1 or more exacerbation in the last year Aged over 18 years Willing to use monitoring devices and complete study questionnaires Adequate English Signed consent form Exclusion Criteria: Pregnancy BMI greater than 45 kg/m2 Nil other, provided inclusion criteria are met.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD patients<br>Group will consist of individuals who have been diagnosed with COPD, living in their home and not recently discharged from the hospital for an exacerbation. | |
| Discharged COPD patients<br>Group will consist of individuals who have been diagnosed with COPD, living in their home, and are being discharged from the hospital for an exacerbation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Track the adherence of DistaSense | To evaluate the adherence of patients using DistaSense, a non-contact vital sign monitor that measures heart rate and respiration rate, we will be tracking the patient dropout rate over the course of the 12 month study period. | 12 months | 
| Understand the patient acceptance of DistaSense | To evaluate the patient acceptance of using DistaSense, a non-contact vital sign monitor that measures heart rate and respiration rate, we will be requesting patients complete a Technology Assessment Model Fast Form (TAM-FF) every 3 months during the 12 month trial period. | 12 months | 
| Ability to detect COPD exacerbations | To evaluate the ability of a non-contact remote monitoring techniques to detect exacerbations of COPD. | 3 - 12 months |
Human Bronchial Microdialysis in Open Aortic Aneurysm Repair

Study Overview
=================
Brief Summary
-----------------
Elective open aortic aneurysm repair has an overall reported 30 day mortality of 2-6 percent, but in patients more than 65-70 years the mortality is reported to be more than 10 percent. The phenomenon of acute lung injury (ALI)/adult respiratory distress syndrome (ARDS) after infra renal abdominal aneurysm repair caused by ischemia-reperfusion is well established. The degree of disability varies from a light degree of acute respiratory failure to mortality for patients with the same profile of risk. Primary aim is to develop a model that monitors inflammatory marker molecules collected from the bronchial epithelial lining fluid by microdialysis. The method with examination of the bronchial epithelial lining fluid by microdialysis and analysis of multiple inflammation markers as previously done by the investigators group.

Official Title
-----------------
Human Bronchial Microdialysis in Open Aortic Aneurysm Repair

Conditions
-----------------
Acute Lung Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients assigned for elective open aortic surgery Exclusion Criteria: Moderate to severe COPD
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokines in bronchial epithelial lining fluid |  | Within 4 days of surgery |
A Comparison of Specialized Versus Standard Compression After Saphenous Ablation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the use of specialized compression garments, in comparison to standard compression, improves early patient outcomes after endovenous ablation.

Official Title
-----------------
A Comparison of Specialized Versus Standard Compression After Saphenous Ablation

Conditions
-----------------
Varicose Veins

Intervention / Treatment
-----------------
* Procedure: Compression stockings
* Device: compression stockings (Sigvaris )


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and above CEAP Class C2 or C3 disease Incompetence of the great saphenous vein defined a reflux persisting>0.5 seconds in the upright position Planned endovenous ablation of the great saphenous vein Exclusion Criteria: Inability of patient or legal guardian to provide informed consent Previous history of DVT Clinical evidence of significant chronic venous disease (CEAP classes C4, C5, C6) Planned concomitant phlebectomy or sclerotherapy within 4 weeks of endovenous ablation Documented allergy or intolerance to compression stockings Arterial insufficiency as documented by an ankle-brachial index <0.5 Known prothrombotic condition Life expectancy less than 1 year Inability to return for follow-up due to geographic inaccessibility, concurrent medical conditions or substance abuse Weight greater than 220 pounds or height > 6'4

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sigvaris special compression stocking<br> | Device: compression stockings (Sigvaris )<br>* Specialized monoleg compression<br>|
| Active Comparator: Standard Compression<br> | Procedure: Compression stockings<br>* standard 30to 40 mm Hg thigh high compression stockings<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral Recovery After Varicose Veins (BRAVV) score. |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Additional scoring and venous duplex ultrasonography | Behavioral Recovery After Varicose Veins (BRAVV) score at 28 days, Pain score at 7 and 28 days, Bruising score at 7 and 28 days, Venous Clinical Severity Score (VCSS) at 7 and 28 days, venous duplex ultrasonography at 28 days | 7 and 28 days |
Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler

Study Overview
=================
Brief Summary
-----------------
The use of ultrasonography in detecting giant cell arteritis ( GCA) is emerging. Currently, temporal biopsy is the gold standard to diagnose GCA but studies have shown the interest to use B mode ultrasonography. However, until now, the study of velocities in GCA have not been yet performed.

Official Title
-----------------
Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler

Conditions
-----------------
Horton Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with suspicious giant arteritis Exclusion Criteria: patients who have already been treated or diagnosed for giant arteritis

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler | velocimetric temporal arterial study in giant arteritis | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of the halo sign in giant arteritis using B mode ultrasonography | presence or absence of the halo sign in giant arteritis patients | 2 months |
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Official Title
-----------------
Special Investigation for CIBINQO （Long Term）

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: CIBINQO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants receiving this Product for treatment of AD. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively. Exclusion Criteria: 1. Participants previously enrolled in this Study at the same site.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients receiving CIBINQO<br>Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis. | Drug: CIBINQO<br>* Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with adverse drug reactions |  | 156 weeks | 
| Number of Participants with Discontinuation of Treatment |  | 156 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score | IGA Scores: Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week X: Non-responder Imputation | Baseline, 156 weeks | 
| Percentage of Participants with Change From Baseline in Eczema Area and Severity Index (EASI) |  | Baseline, 156 weeks | 
| Percentage of Participants with Change From Baseline in Affected % Body Surface Area (BSA) |  | Baseline, 156 weeks | 
| Percentage of Participants with Change From Baseline in Pruritus Assessment |  | Baseline, 156 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
JAK Inhibitor, Atopic Dermatitis (AD), Abrocitinib, Eczema
Measurement of Anaesthesia-depth Trough Narcotrend TM in Patients Undergoing Electro-Convulsion-Therapy (ECT)- Influence of Anasthesia Depth on Quality of Convulsion

Study Overview
=================
Brief Summary
-----------------
The Electro-Convulsion-Therapy (ECT) is a well accepted treatment option in severe depression. The quality of ECT is evaluated basing on minimal seizure duration (>15sec), the sympathic response and the postictal EEG-suppression. For the treatment general anaesthesia is needed. On the other hand anaesthesia strongly influences the quality of the seizure. The goal is to find an anaesthesia-depth that is needed for the well-being of the patient and allows a good ECT. In daily routine the dose of anesthetic agents and the assesment of anesthesia-depth is based on the subjective estimation of the anesthetist and also on ealier interventions. The aim of the study is to assess any correlation between measured anesthesia-depth using the Narcotrend TM and the Quality of the ECT.

Official Title
-----------------
Measurement of Anaesthesia-depth Trough Narcotrend TM in Patients Undergoing Electro-Convulsion-Therapy (ECT)- Influence of Anaesthesia Depth on Quality of Convulsion - A Non-Intervention Trial

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Device: Narcotrend TM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA (American Society of Anesthesiologists) Physical Satus I-3 >18 years < 90 years Signed informed consent Exclusion Criteria: Refusal of the patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Narcotrend TM|Measurement of anesthesia depth|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of anesthesia depth measured by Narcotrend TM and quality of ECT treatment |  | 1 day |
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

Study Overview
=================
Brief Summary
-----------------
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)

Official Title
-----------------
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: Rosuvastatin
* Procedure: aortic pulse wave velocity measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, between 50 and 80 years of age, end stage renal failure patients receiving hemodialysis Exclusion Criteria: Received statins within past 6 months, a clear indication for use of lipid altering drug, contra indication for lipid altering drug, history of statin induced myopathy items in very

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rosuvastatin|nan|
|Procedure: aortic pulse wave velocity measurements|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the effect of rosuvastatin compared to placebo on the aortic pressure wave in hemodialysis patients (at 3 months/ 6 months and 12 months). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high blood cholesterol levels